Bicocca Open Archive

Logo unimib boa
BANDERA, ALESSANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.028
AS - Asia 3.212
EU - Europa 2.220
SA - Sud America 500
Continente sconosciuto - Info sul continente non disponibili 421
AF - Africa 87
OC - Oceania 9
Totale 11.477
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.707
SG - Singapore 1.107
CN - Cina 698
VN - Vietnam 488
IT - Italia 416
HK - Hong Kong 386
BR - Brasile 380
RU - Federazione Russa 375
DE - Germania 295
IE - Irlanda 259
CA - Canada 258
SE - Svezia 245
GB - Regno Unito 124
UA - Ucraina 109
FR - Francia 100
IN - India 99
BD - Bangladesh 76
FI - Finlandia 70
DK - Danimarca 54
AR - Argentina 51
ID - Indonesia 44
TR - Turchia 44
IQ - Iraq 42
KR - Corea 38
ZA - Sudafrica 38
NL - Olanda 32
ES - Italia 28
JP - Giappone 28
MX - Messico 28
AT - Austria 24
PL - Polonia 24
PK - Pakistan 23
SA - Arabia Saudita 22
BE - Belgio 15
UZ - Uzbekistan 15
PH - Filippine 14
EC - Ecuador 13
VE - Venezuela 12
CL - Cile 11
IR - Iran 11
CO - Colombia 10
MA - Marocco 9
MY - Malesia 9
AU - Australia 8
HN - Honduras 8
KE - Kenya 8
NP - Nepal 8
UY - Uruguay 8
CH - Svizzera 7
PY - Paraguay 7
AZ - Azerbaigian 6
CZ - Repubblica Ceca 6
EG - Egitto 6
ET - Etiopia 6
IL - Israele 6
JO - Giordania 6
LT - Lituania 6
AE - Emirati Arabi Uniti 5
CR - Costa Rica 5
EU - Europa 5
JM - Giamaica 5
LB - Libano 5
TH - Thailandia 5
TN - Tunisia 5
TW - Taiwan 5
BG - Bulgaria 4
BO - Bolivia 4
BZ - Belize 4
PE - Perù 4
PT - Portogallo 4
AL - Albania 3
BH - Bahrain 3
DO - Repubblica Dominicana 3
HR - Croazia 3
KH - Cambogia 3
LV - Lettonia 3
ML - Mali 3
MN - Mongolia 3
OM - Oman 3
RO - Romania 3
SN - Senegal 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BB - Barbados 2
GR - Grecia 2
MD - Moldavia 2
NG - Nigeria 2
PS - Palestinian Territory 2
QA - Qatar 2
SC - Seychelles 2
SI - Slovenia 2
BS - Bahamas 1
BT - Bhutan 1
BY - Bielorussia 1
DZ - Algeria 1
EE - Estonia 1
GT - Guatemala 1
HT - Haiti 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LK - Sri Lanka 1
Totale 11.048
Salva come PNG Salva come JPEG
Città #
Singapore 669
Ashburn 423
Hong Kong 379
Ann Arbor 375
San Jose 371
Fairfield 276
Chandler 271
Dublin 253
Houston 192
Woodbridge 186
Frankfurt am Main 181
Toronto 176
Wilmington 174
New York 162
Ho Chi Minh City 144
Dallas 143
Los Angeles 142
Milan 134
Hanoi 116
Seattle 106
Jacksonville 102
Beijing 98
Dearborn 96
Cambridge 94
Santa Clara 82
Chicago 77
Princeton 71
The Dalles 67
Hefei 65
Shanghai 51
Buffalo 50
Nanjing 42
Lauterbourg 40
Helsinki 39
Council Bluffs 37
São Paulo 35
Seoul 33
Lawrence 32
Altamura 31
Moscow 31
Ottawa 28
Rome 28
Munich 27
Tokyo 26
Denver 21
Fremont 21
London 21
San Diego 21
Florence 20
Kent 20
Nanchang 20
Boardman 19
Jakarta 19
Lachine 19
Baghdad 18
Dong Ket 18
Brooklyn 17
Nuremberg 17
Rio de Janeiro 17
Amsterdam 16
Hangzhou 16
Orem 16
Da Nang 15
Brussels 14
Warsaw 14
Guangzhou 13
Salt Lake City 13
Vienna 13
Andover 12
Chennai 12
Columbus 12
Edmonton 12
Shenyang 12
Tashkent 12
Washington 12
Brasília 11
Jeddah 11
Johannesburg 11
Redondo Beach 11
Atlanta 10
Changsha 10
Durban 10
Haiphong 10
Hebei 10
Kunming 10
Montreal 10
Boston 9
Quận Bình Thạnh 9
San Francisco 9
Biên Hòa 8
Buenos Aires 8
Bắc Ninh 8
Ha Long 8
Kiev 8
Miami 8
Norwalk 8
Paris 8
Phoenix 8
Poplar 8
Pune 8
Totale 6.886
Salva come PNG Salva come JPEG
Nome #
Microbiota in ICU, not only a gut problem 360
Similar success rates but lower incidence of telaprevir-related rash in HIV/HCV coinfected as compared to HCV-monoinfected patients treated with triple anti-HCV therapy 352
Impact of orotracheal intubation and mechanical ventilation on the microbiota of the lung in the development of Ventilator- Associated Pneumonia 334
Effects of autologous stem cell transplantation in HIV: searching for the origins of viral replication in settings of profound CD4(+) T cell depletion 326
A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: Worth the risk? 323
Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated with the Evolution of Cognitive Performance in HIV-Infected Patients 323
Brachial and central blood pressure in HIV-infected subjects 318
Strategies to limit immune-activation in HIV patients 312
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 309
Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: The IMMUNEF clinical trial 296
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 295
Customization of LC-MS-based proteomic workflows for biological studies in the clinical field 292
ECMO: An alternative support for acute respiratory failure caused by tuberculosis? 285
Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen 283
Combination antifungal therapy for invasive mold infections among pediatric patients with hematological malignancies: Data from a real-life case-series 269
Plasma Proteomic Variables Related to COVID-19 Severity: An Untargeted nLC-MS/MS Investigation 265
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: Results of the "cOPA" pilot randomized trial 265
A case of classic neuromyelitis optica (Devic's syndrome) triggered by pegylated-interferon α 264
Impact of dexamethasone on the incidence of ventilator-associated pneumonia in mechanically ventilated COVID-19 patients: a propensity-matched cohort study 251
Unmasking tuberculosis in the era of antiretroviral treatment 247
Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: Relapse or late IRIS? 246
Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients 240
KIR-HLA genotypes in HIV-infected patients lacking immunological recovery despite effective antiretroviral therapy 239
Use of CXCR4-antagonist for haematopoietic stem cell mobilization in HIV-infected patients with haematological malignancies 237
Untargeted mass spectrometry approach to study SARS-CoV-2 proteins and characterize human plasma and saliva proteome in COVID-19 patients. 236
Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations 231
Under representation of the inhibitory KIR3DL1 molecule and the KIR3DL1+/BW4+ complex in HIV exposed seronegative individuals 217
SARS-CoV-2 RNA in plasma samples of COVID-19 affected individuals: a cross-sectional proof-of-concept study 213
Predictors of COVID-19 Readmission Among Patients Previously Hospitalized for SARS-CoV-2 210
HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial 209
Plasma proteome investigation of COVID-19 patients with different outcomes through an untargeted label-free LC-MS/MS approach. 208
Characterization of immune failure by monocyte activation phenotypes in HIV-infected patients receiving antiretroviral therapy 207
Early changes in adhesion molecules expression and endothelial function in patients initiating ART with Atazanavir or Lopinavir 207
High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects Data from the ICONA Foundation Cohort 207
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 190
Plasma proteomic signatures related to COVID-19 disease severity by an untargeted nLC-ESI-MS/MS approach 190
Arterial structural and functional effects of two different antiretroviral therapy protocol on naïve HIV-infected subjects 185
Exogenous reinfection of tuberculosis in a low-burden area 184
Corrigendum: The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study(Front. Med., (2022), 9, (850858), 10.3389/fmed.2022.850858) 183
Characterization of SARS-CoV-2 proteins and human proteome in COVID-19 patients’ saliva and plasma: an untargeted mass spectrometry approach 175
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? 175
Unmasked tuberculosis or lymphoma in late AIDS presenters: A difficult differential diagnosis 174
Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study 173
Plasma, Intracellular and Lymph Node Antiretroviral Concentrations and HIV DNA Change During Primary HIV Infection: Results from the INACTION P25 Study 171
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir 167
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 150
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 147
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 134
Occupational HIV infection in a research laboratory with unknown mode of transmission: a case report 3
Totale 11.477
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.700
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.700
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022474 15 21 46 60 20 48 21 36 23 55 29 100
2022/2023959 102 316 74 113 40 129 10 68 65 8 23 11
2023/2024754 19 14 46 32 92 217 144 37 52 23 6 72
2024/20251.813 88 181 125 90 147 78 131 38 206 318 155 256
2025/20264.842 675 331 438 467 537 243 592 189 349 438 309 274
2026/2027116 116 0 0 0 0 0 0 0 0 0 0 0
Totale 11.477